Tavaborole

🧮 Dose calculator

Onychomycosis · Regimen source: FDA Tavaborole · 2

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Tavaborole · 8.1

  “Risk Summary There are no available data on tavaborole topical solution use in pregnant women to inform a drug associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Tavaborole · 8.2

  “Risk Summary There is no information available on the presence of tavaborole in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production after topical application of tavaborole topical solution to women who are breastfeeding. tavaborole topical solution is systemically …”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Tavaborole · 8.4

  “The safety and efficacy of tavaborole topical solution were established in patients 6 years of age and older.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Tavaborole · 8.5

  “In clinical trials of 791 subjects who were exposed to tavaborole topical solution, 19% were 65 years of age and over, while 4% were 75 years of age and over.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.